NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $40.00 price objective on the stock.

Several other equities research analysts have also recently issued reports on NRXP. BTIG Research restated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Monday, August 25th. Zacks Research raised shares of NRx Pharmaceuticals to a “hold” rating in a research note on Wednesday, September 10th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a research report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, NRx Pharmaceuticals presently has an average rating of “Buy” and an average price target of $34.50.

NRx Pharmaceuticals Stock Performance

NASDAQ:NRXP opened at $3.34 on Wednesday. NRx Pharmaceuticals has a one year low of $1.10 and a one year high of $6.01. The stock has a market cap of $66.17 million, a PE ratio of -1.49 and a beta of 1.74. The stock has a 50 day moving average price of $2.76 and a 200 day moving average price of $2.63.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings data on Monday, August 18th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.67). As a group, analysts predict that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC acquired a new position in NRx Pharmaceuticals during the fourth quarter worth $56,000. Millennium Management LLC purchased a new stake in shares of NRx Pharmaceuticals in the 4th quarter valued at $61,000. Geode Capital Management LLC lifted its stake in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after acquiring an additional 37,598 shares in the last quarter. Finally, Anson Funds Management LP boosted its holdings in NRx Pharmaceuticals by 535.1% during the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock valued at $2,417,000 after acquiring an additional 993,401 shares during the period. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.